<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_TU-Delft_NovelPeptides"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:TU-Delft/NovelPeptides">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:TU-Delft/NovelPeptides&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:TU-Delft/NovelPeptides&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:TU-Delft/NovelPeptides&amp;action=history">History               </A></LI><LI style="color:white;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:TU-Delft/NovelPeptides" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform">Â </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:TU-Delft/NovelPeptides</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2013.igem.org</H3><UL id="menu"><LI><A href="https://2013.igem.org/Team:TU-Delft">Home</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Team">Team</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Project">Project</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/ProjectOverview">Overview</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Sensing">Sensing Device</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Peptides">Peptide Production</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/PeptideCharacterization">Peptide Characterization</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Timer">Timer</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Killswitch">Kill switch</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/FinalApplication">Band Aid Application</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/new_Standard">New Standard Approach</A></LI></UL><LI><A href="https://2013.igem.org/Team:TU-Delft/Achievements">Achievements</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Notebook">Notebook</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Planning">Planning</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Protocols">Protocols</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Parts">Parts</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Modeling">Modeling</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Timer_Plus_Sumo">Timer plus SUMO</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/KillSwitch">Kill Switch</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Timer-Sumo-KillSwitch">Timer-SUMO-Kill Switch</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/BandAid">Band Aid</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/NovelPeptides">Novel Peptides</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Safety">Safety</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/human practice">Human Practice</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/novel_approach">Novel Approach</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/BandAidSelection">BandAid</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Zephyr"> Zephyr  </A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Zephyr_How"> Zephyr: How? </A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/SynBioData">Wiki Interviews</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Meet_with_RIVM">Meeting with RIVM</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Summer Festival">Human Outreach</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Extras">Extras</A></LI><LI><A href="https://2013.igem.org/Http://2013.igem.org/Team:TU-Delft/Acknowledgements">Acknowledgements</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Collaborations">Collaborations</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/PR">PR</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/iGemNetherlandsCollaboration">iGEM Netherlands</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/MeetChristopherVoigt">Meet with Christopher Voigt</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Gallery">Photo Gallery</A></LI><LI><A href="https://2013.igem.org/Team:TU-Delft/Brainstorm">Brainstorm</A></LI><DIV style="margin-left:30px;margin-right:30px; width:900px;float:left;"><H2 align="center"><SPAN class="mw-headline" id="Novel_Peptides">Novel Peptides</SPAN></H2><P align="justify">
The antimicrobial peptide(AMPs) field is growing rapidly in response to the demand
for novel antimicrobial agents. In particular AMPs are promising candidates
in the fight against antibiotic-resistant pathogents due to their low toxicity,
and broad range of activity. Antimicrobial peptides are generally between 12 and 50 amino acids long. These peptides
include two or more positively charged residues provided by arginine, lysine
or, in acidic environments, histidine, and a large proportion of hydrophobic residues <A href="https://2013.igem.org/Team:TU-Delft/Ref" target="blank">[1]</A>.
</P><P align="justify">
Due to the fact that AMPs constitute a current research area, both the
knowledge and the experimentally validated data are rapidly increasing.It
was decided to use these data in order to create novel peptides which will
be high toxic for <I>S. aureus</I> but low toxic for <I>E. coli</I>. The method that was
developed(Figure 1) is described in the following sections.
</P><CENTER>
Figure 1: Schematic Description of the Method
</CENTER><H2 align="center">Data and Feature extraction</H2><P align="justify">
The necessary data were acquired from the <A href="http://www.bicnirrh.res.in/antimicrobial/" style="text-decoration: none"><FONT color="#0080FF" size="3">CAMP: Collection of Anti-Microbial
Peptides Database</FONT></A>. The database contains 3789 records with MIC values but
only the records that target both <I>E. coli</I> and <I>S. aureus</I>(and are experimentally validated) were taken into account. The acquired records were seperated into 4 classes based on the MIC values:
</P><UL style="list-style-type: circle"><LI><B>class 0:</B> Toxic for both <I>S. aureus</I> and <I>E. coli</I></LI><LI><B>class 1:</B> Toxic for <I>S. aureus</I> but not for <I>E. coli</I></LI><LI><B>class 2:</B> Toxic for <I>E. coli</I> but not for <I>S. aureus</I></LI><LI><B>class 3:</B> Non Toxic for both <I>E. coli</I> and <I>S. aureus</I></LI></UL>
The next step is related to the feature extraction for each one of the
collected peptides.The resulting number of features per sequence is 21 <A href="https://2013.igem.org/Team:TU-Delft/Ref" target="blank">[1][2][3]</A>
.In particular, the attributes for each peptide are either general such as the length of the sequence or specific based on AMPs properties.A list of them is presented underneath:
<UL style="list-style-type: circle"><LI>length </LI><LI>charge </LI><LI>prolines' frequency</LI><LI>glycines' frequency</LI><LI>hydrophobic residues appearance</LI><LI>hydropathy</LI><LI>C terminus</LI><LI>N terminus</LI><LI>polarity</LI></UL>

The N and C terminus were examined only for 3 positions due to the different size of each peptide. 
<H2 align="center">Rule Learning</H2><P align="justify">
After creating the final data set, a machine learning toolkit, <A href="http://www.cs.waikato.ac.nz/ml/weka/" style="text-decoration: none"><FONT color="#0080FF" size="3">WEKA</FONT></A>, was used. In particular, WEKA contains a collection of machine learning algorithms for data mining tasks. In our case, it was decided to use nnge algorithm in order to perform association rule mining  <A href="https://2013.igem.org/Team:TU-Delft/Ref" target="blank">[4]</A><A href="https://2013.igem.org/Team:TU-Delft/Ref" target="blank">[6]</A>(Figure 2).
<CENTER>
Figure 2: NNge Description
</CENTER></P><P align="justify">By the term association rule mining, a method for  discovering interesting relations between variables  in data sets is described.In that way, it is possible to discover rules that represent the class of interest and create our novel peptides!Some of the rules identified can be seen in Figure 3.</P><CENTER>
Figure 3: Some rules discovered by NNge
</CENTER><P align="justify">
In order to give a better understanding of the design process, the rules that referred to the class of interest(class 1) are presented below.

<UL><LI>13-14/23/24/33/37/40/44 aa length</LI><LI>charge of 1-4 or 10</LI><LI>hydropathy with a minimum value of -0.37 and a maximum value of 1.82(dependent on the peptide length)</LI><LI>the 3 first amino acids are either FLP or GLL</LI><LI>the 3 last amino acids are RLL, GLL or FGL</LI><LI>in between N and C terminus amino acid sequence:0-2 prolines</LI><LI>in between N and C terminus amino acid sequence:0-4 or 7 glycines</LI><LI> frequencies for specific hydrophobic residues, like tryptophan: 0 or 1 or 3</LI></UL></P><H2 align="center">Model Evaluation</H2><P align="justify">
In order to evaluate the performance of our model, we are interested in investigating the ability of the model to correctly predict or separate the classes. For that reason, the measurements accuracy,  precision , recall and F-measure are computed. A brief explanation for each measurement is presented below.


<UL style="list-style-type: circle"><LI><B>Accuracy</B>: the overall correctness of the model </LI><LI><B>Precision:</B>percent of positive predictions which are correct </LI><LI><B>Recall:</B>true positive rate (percent of positive cases that you can catch)</LI><LI><B>F-measure</B>:a measure that combines precision and recall</LI></UL>
In our case, we succeeded in the aforementioned results:
<B>Accuracy:</B>    94.4149 %
<B>Detailed Accuracy by class</B><CENTER><TABLE border="1"><TBODY><TR><TH>Class</TH><TH>Precision</TH><TH>Recall</TH><TH>F-measure</TH></TR><TR><TD>1</TD><TD>0.955</TD><TD>0.986</TD><TD>0.97</TD></TR><TR><TD>2</TD><TD>0.917     </TD><TD>0.611     </TD><TD>0.733      </TD></TR><TR><TD>3</TD><TD>0.963   </TD><TD>0.867         </TD><TD>0.912            </TD></TR><TR><TD>4</TD><TD>0.737        </TD><TD>0.875              </TD><TD>0.8            </TD></TR><TR><TD>Weighted Avg.    </TD><TD>0.945            </TD><TD>0.944                 </TD><TD>0.942            </TD></TR></TBODY></TABLE></CENTER></P><H2 align="center">Final Created Peptides</H2><P align="justify">
The rules that generated are taken into consideration in order to create our final peptides.First of all it was decided to create peptides which are 13 amino acids long in order to avoid post translation modification. The next step was to set the amino acids for the N and C terminus because it was proven to be of great importance for the the toxicity and selectivity of the peptides. As it has been already described the 3 first amino acids, N terminus, are fixed and can be either  FLP or GLL. Same is the case for the 3 last amino acids, C terminus, which can be only RLL, GLL or FGL for class 1.

We also set the number of prolines, glycines and specific hydrophobic
amino acids to satisfy the rules due to the fact that  the amino acid composition of these specific amino acids proved to be of great importance for the AMPs. The rest of the amino acids were chosen so as to satisfy the remaining rules.
</P><P align="justify">
 It is also necessary to be mentioned that we designed our peptides by taking into consideration their hydrophobic nature. We tried to design them in a way that they will both satisfy the rules and they will not be highly hydrophobic. In that way we ensured that the peptides will not be toxic for humans as the toxicity to humans is directly related and influenced by the peptide's hydrophobic nature <A href="https://2013.igem.org/Team:TU-Delft/Ref" target="blank">[5]</A>.
</P><P align="justify">
Finally it was also significant to ensure that the synthesized peptide would have a high probability of working. For that reason after synthesizing the peptides we also checked the aforementioned criteria.
</P><UL style="list-style-type: circle"><LI><A href="http://web.expasy.org/protparam/" style="text-decoration: none"><FONT color="#0080FF" size="3">Testing hydropathy</FONT></A></LI><LI><A href="https://www.genscript.com/ssl-bin/site2/peptide_calculation.cgi" style="text-decoration: none"><FONT color="#0080FF" size="3">Testing hydrophobicity and charge </FONT></A></LI><LI><A href="https://www.ghttp://www.bicnirrh.res.in/" style="text-decoration: none"><FONT color="#0080FF" size="3">BLAST against known AMPs </FONT></A></LI></UL><P align="justify">
The amino acid sequences for each peptide and their properties are depicted underneath.
</P><OL><LI>peptidor :<B> GFGLCKNKAFGLL</B>Â <P>Figure 4: peptidor propertiesÂ Â Â Â 
Figure 5: peptidor amino acid composition

</P><P align="justify">
The peptidor peptide was also proven to have similarity with the MIRJA antimicrobial peptide(E-
Value 6.5). The specific peptide do not target <I>E. coli</I> but it targets Gram positive bacteria.
</P>
We also run SVM classifier in CAMP database for predicting the antimicrobial nature of the peptide.
<TABLE border="1" bordercolor="#000000" style="background-color:#FFFFFF" width="100%" cellpadding="3" cellspacing="3"><TBODY><TR><TD>Sequence Id</TD><TD>Class</TD><TD>Probability</TD></TR><TR><TD>Unknown</TD><TD>AMP</TD><TD>0.961</TD></TR></TBODY></TABLE></LI><LI>derpini: <B>FLPILGVARKGLL </B>Â <P>Figure 6: derpini propertiesÂ Â Â Â 
Figure 7: derpini amino acid composition

</P><P align="justify">
The derpini peptide was  proven to have similarity with both Vespid chemotactic peptide
5h and Temporin-1CSb(E-value: 3.6). Temporin is an AMP which has MIC = 128  Î¼M for <I>E. coli</I> and MIC = 8  Î¼M for <I>S. aureus</I>. The other AMP is inactive against <I>E. coli</I> but active against <I>S. aureus</I>.</P>
After running SVM classifier in CAMP the peptide was predicted as antimicrobial.
<TABLE border="1" bordercolor="#000000" style="background-color:#FFFFFF" width="100%" cellpadding="3" cellspacing="3"><TBODY><TR><TD>Sequence Id</TD><TD>Class</TD><TD>Probability</TD></TR><TR><TD>Unknown</TD><TD>AMP</TD><TD>0.955</TD></TR></TBODY></TABLE></LI><LI>staphycine: <B> FLPLLASLFSRLL </B>Â <P>Figure 8: staphycine propertiesÂ Â Â Â 
Figure 9: staphycine amino acid composition
</P><P align="justify">
staphycine was proven to have similarity with Temporin-1CSb(E-value: 0.011).
</P>
Temporin has MIC = 70 Î¼M for E.Coli and MIC = 2 Î¼M for S.Aureus.
<TABLE border="1" bordercolor="#000000" style="background-color:#FFFFFF" width="100%" cellpadding="3" cellspacing="3"><TBODY><TR><TD>Sequence Id</TD><TD>Class</TD><TD>Probability</TD></TR><TR><TD>Unknown</TD><TD>AMP</TD><TD>0.862</TD></TR></TBODY></TABLE></LI></OL><P align="justify">
Our lab people test our synthesized peptides in the lab!!!The peptidor peptide worked well. It was highly toxic against <I>S. delphini</I> with an MIC of 40Î¼Î, but showed low toxicity against both <I>E. coli</I> and COS-1 cells(Figure 10A, Figure 12A, Figure 13).
Staphycine peptide worked as expected,  being highly toxic to <I>S.delphini</I>(MIC of 30-40Î¼M) but not toxic to <I>E. coli</I> and COS-1 cells(Figure 10B, Figure 12B, Figure 13). Last but not least, derpini did not work as expected as it was proven not to be toxic for <I>S. delphini</I> . 
</P><P>Figure 10: MICs of peptidor. 10A: peptidor on <I>S. delphini</I>, 10B: peptidor on <I>B. subtilus</I></P><P>Figure 11: MICs of Staphicine. MICs of staphycine 11A:staphycine on <I>S. delphini</I>, 11B: staphycine on <I>B. subtilus</I></P><P>Figure 12: 12A peptidor on <I>E. coli</I>, 12B staphycine on <I>E. coli</I></P><P>Figure 13: Toxicity test of AMPs on COS-1 cells </P>


For more information, check our <A href="https://2013.igem.org/Team:TU-Delft/PeptideCharacterization" target="blank">lab pages</A>!

<H2 align="center">Discussion</H2><P align="justify">
As observed there is a large set of generated rules and some overlapping rules between the classes. It is highly probable that one peptide failed to work due to this reason. The are limitation to the specific model and this is related not only to the fact that the experimentally validated data set is of small size but also to the fact that the number of samples that belong to the class of interest is limited compared to the other classes. In the future, it is possible to improve the model by performing a better feature selection and/or using different algorithms. However, it is necessary for all the data that are currently available to be experimentally validated and more to be included in the current databases.
</P></DIV><DIV class="printfooter">
Retrieved from &quot;<A href="http://2013.igem.org/Team:TU-Delft/NovelPeptides">http://2013.igem.org/Team:TU-Delft/NovelPeptides</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:TU-Delft/NovelPeptides" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:TU-Delft/NovelPeptides" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:TU-Delft/NovelPeptides&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:TU-Delft/NovelPeptides&amp;oldid=337848" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2013.igem.org:Privacy_policy" title="2013.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2013.igem.org:General_disclaimer" title="2013.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>